TLDR: Cognizant’s AI Lab has secured two new U.S. patents in 2025, bringing its total to 59 issued patents with 23 more pending, demonstrating significant advancements in AI optimization. The lab also received a Gold Award at GECCO 2025 for its RHEA project and open-sourced its Neuro AI Multi-Agent Accelerator platform, reinforcing its commitment to pioneering transformative AI technologies.
Cognizant (Nasdaq: CTSH) has announced significant strides in its artificial intelligence research and development, with its AI Lab securing two new U.S. patents in the first half of 2025. These additions bring the AI Lab’s total U.S. patent count to 59, with an additional 23 patents currently pending. Globally, the lab holds over 120 patents, issued or pending, underscoring its robust intellectual property portfolio in the AI domain.
The newly granted patents highlight key innovations from Cognizant’s AI research. U.S. Patent No. 12,282,845, issued on April 22, 2025, covers a method for Multi-objective Coevolution of Deep Neural Network Architectures. This innovation aims to enhance model performance and resource efficiency, with potential applications spanning from medical image classification to natural language processing. The second patent, U.S. Patent No. 12,292,944, issued on May 6, 2025, outlines a method for optimizing loss functions through Taylor Series Expansion. This method is designed to improve training efficiency and bolster model robustness, particularly in scenarios with limited data. These patents were developed by Cognizant researchers including Dr. Jason Liang, Dr. Elliot Meyerson, and Professor Risto Miikkulainen.
In addition to its patent achievements, Cognizant’s AI Lab received the prestigious Gold Award for Human-Competitive Results at the Genetic and Evolutionary Computation Conference (GECCO) 2025, held in Malaga, Spain. This recognition was for their groundbreaking work on RHEA (Realizing Human Expertise through AI). Developed by Dr. Elliott Meyerson and Professor Risto Miikkulainen, RHEA utilizes evolutionary AI to distill and recombine hundreds of models generated by human expert teams, notably those submitted to the XPRIZE Pandemic Response Challenge, into refined decision strategies.
Further demonstrating its commitment to advancing AI accessibility and innovation, Cognizant earlier this year open-sourced its Neuro AI Multi-Agent Accelerator platform. This platform is designed to help businesses accelerate the development and adoption of AI agents, facilitating adaptive operations, real-time decision-making, and personalized customer experiences tailored to client-defined objectives and oversight.
Babak Hodjat, CTO of AI at Cognizant, emphasized the company’s dedication to innovation, stating, “Being granted two new U.S. patents in the first half of 2025—bringing our AI Lab’s U.S. total to 59 with 23 more patents pending—underscores our relentless pace of innovation.” He added, “Couple this with a Gold Award at GECCO and these milestones reflect our deep commitment to pioneering transformative AI technologies and turning cutting-edge ideas into real-world impact.”
Also Read:
- NTT DATA Earns Emerging Leader Recognition in Gartner’s 2025 Guide for Generative AI Services
- Newsweek Unveils Leading Innovators at Inaugural 2025 AI Impact Awards
The Cognizant AI Lab, which opened its flagship San Francisco-based AI research facility in March 2024, focuses on maximizing human potential with Decision AI. This form of AI combines generative AI, multi-agent architecture, deep learning, and evolutionary AI to create sophisticated decision-making systems, enabling organizations to rapidly build AI that optimizes decision-making for revenue growth and societal progress.
